Exicure (XCUR) Retained Earnings (2016 - 2026)
Exicure's (XCUR) quarterly Retained Earnings came in at -$206.0 million in Q1 2026, down 4.99% YoY from -$216.8 million in Q1 2025, and down 198.99% on a QoQ basis from $208.1 million in Q4 2025.
Exicure (XCUR) Retained Earnings (2016 - 2026) Analysis & Trends
Exicure (XCUR) has 11 years of Retained Earnings data on file, last reported at -$206.0 million in Q1 2026.
- Quarterly Retained Earnings fell 4.99% year-over-year to -$206.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$206.0 million (down 4.99% YoY) and the FY2025 annual result came in at $208.1 million, up 204.45% from the prior year.
- Retained Earnings slipped to -$206.0 million in Q1 2026, from $208.1 million in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of $208.1 million in Q4 2025 to a low of -$206.0 million in Q1 2026.
- A 5-year average of -$43.3 million and a median of -$177.1 million in 2023 frame the typical range for Retained Earnings.
- Annual changes were most pronounced in 2022 — Retained Earnings tumbled 19104400.0% — and 2023, when it surged 3850580.0%.
- Tracing XCUR's Retained Earnings over 5 years: stood at -$172.6 million in 2022, then retreated by 9.8% to -$189.6 million in 2023, then retreated by 5.12% to -$199.3 million in 2024, then surged by 204.45% to $208.1 million in 2025, then plunged by 198.99% to -$206.0 million in 2026.
- The last three Retained Earnings figures came in at -$206.0 million (Q1 2026), $208.1 million (Q4 2025), and -$201.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 4.38 Bn |
| 10 | Exicure | 7.27 Mn | 7.27 Mn | - | 208.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -206.04 Mn |
| Dec 31, 2025 | 208.14 Mn |
| Sep 30, 2025 | -201.31 Mn |
| Jun 30, 2025 | 207.64 Mn |
| Mar 31, 2025 | -196.25 Mn |
| Dec 31, 2024 | -199.26 Mn |
| Sep 30, 2024 | 193.63 Mn |
| Jun 30, 2024 | 192.60 Mn |
| Mar 31, 2024 | -190.39 Mn |
| Dec 31, 2023 | -189.56 Mn |
| Sep 30, 2023 | -188.08 Mn |
| Jun 30, 2023 | 192.52 Mn |
| Mar 31, 2023 | -177.06 Mn |
| Dec 31, 2022 | -172.65 Mn |
| Sep 30, 2022 | -191.05 Mn |
| Jun 30, 2022 | -5,000.00 |
| Mar 31, 2022 | 181.64 Mn |
| Dec 31, 2021 | 181.30 Mn |
| Sep 30, 2021 | -1,000.00 |
| Jun 30, 2021 | 169.34 Mn |